An open-label study to evaluate switching from an SSRI or SNRI to tiagabine to alleviate antidepressant-induced sexual dysfunction in generalized anxiety disorder

Annals of Clinical Psychiatry

Volumn 19, Issue 1, 2007, Pages 25-30

  Schwartz, Thomas L ^a   Nasra, George S ^b   Ashton, Adam K ^c   Kang, David ^a   Kumaresan, Hari ^a   Chilton, Mark ^a   Bertone, Francesca ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b Unity Health Systems   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TIAGABINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENERALIZED ANXIETY DISORDER; HAMILTON SCALE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MALE; MONOTHERAPY; NAUSEA; PRIORITY JOURNAL; RATING SCALE; SEXUAL DYSFUNCTION; TREATMENT OUTCOME;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY DISORDERS; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GABA AGONISTS; HUMANS; MALE; MIDDLE AGED; NIPECOTIC ACIDS; SEROTONIN UPTAKE INHIBITORS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

EID: 33947326904     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: 10.1080/10401230601163535     Document Type: Article

References (33)

1. Kessler RC, McGonagle KA, Zhao S, et al.: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:8-19
2. Wittchen HU, Zhao S, Kessler RC, et al.: DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:355-364
3. Rickels K, Schweizer E: The clinical course and long-term management of generalized anxiety disorder. J Clin Psychopharmacol 1990; 10 (Suppl):101S-110S
4. Angst J, Vollrath M: The natural history of anxiety disorders. Acta Psychiatr Scand 1991; 84:446-452
5. Massion AO, Warshaw MG, Keller MB: Quality of life and psychiatric morbidity in panic disorder and generalized anxiety disorder. Am J Psychiatry 1993; 150:600-607
6. Kaufman J, Charney D: Comorbidity of mood and anxiety disorders. Depress Anxiety 2000; 12 (Suppl 1):69-76
7. Kessler RC, Wittchen HU: Patterns and correlates of generalized anxiety disorder in community samples. J Clin Psychiatry 2002; 63 (Suppl 8):4-10
8. Davidson JRT: Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 2001; 62 (Suppl 11):46-60
9. Rickels K, Rynn M: Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 2002; 63 (Suppl 14):9-16
10. Clayton AH, Warnock JK, Kornstein SG, et al.: A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry 2004; 65:62-67
11. Montgomery SA, Henry J, McDonald G, et al.: Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 1994; 9:47-53
12. Bonierbale M, Lancon C, Tignol J: The ELIXIR study: Evaluation of sexual dysfunction in 4557 depressed patients in France. Curr Med Res Opin 2003; 19:114-124
13. Rosen RC, Marin H: Prevalence of antidepressant-associated erectile dysfunction. J Clin Psychiatry 2003; 64 (Suppl 10):5-10
14. Derogatis LR: Sexual function and quality of life: Endpoints and outcomes. J Gend Specif Med 2001; 4:35-42
15. Rosenberg KP, Bleiberg KL, Koscis J, Gross C: A survey of sexual side effects among severely mentally ill patients taking psychotropic medications: Impact on compliance. J Sex Marital Ther 2003; 29:289-296
16. Montejo AL, Llorca G, Izquierdo JA: Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. J Clin Psychiatry 2001; 62 (Suppl 3):10-21
17. Nutt DJ: Neurobiological mechanisms in generalized anxiety disorder. J Clin Psychiatry 2001; 62 (Suppl 11):22-27
18. Lydiard RB: The role of GABA in anxiety disorders. J Clin Psychiatry 2003; 64 (Suppl 3):21-27
19. Fink-Jensen A, Suzdak PD, Swedberg MD, et al.: The gammaaminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats. Eur J Pharmacol 1992; 220:197-201
20. Borden LA, Murali Dhar TG, Smith KE, et al.: Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur J Pharmacol 1994; 269:219-224
21. Rosenthal M: Tiagabine in the treatment of generalized anxiety disorder: A randomized, open-label, clinical trial with paroxetine as a positive control. J Clin Psychiatry 2003; 64:1245-1249
22. Pollack MH, Roy-Byrne PP, Van Ameringen M, et al.: The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: Results of a placebo-controlled study. J Clin Psychiatry 2005; 66:1401-1408
23. Sheehan DV, Lecrubier Y, Sheehan KH, et al.: The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin Psychiatry 1998; 59(Suppl 20): 22-33
24. Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 1959; 32:50-55.
25. Zigmond AS, Snaith RP: The Hospital Anxiety and Depression Scale. Acta Pscyhiatr Scand 1983; 67:361-370
26. McGahuey CA, Gelenberg AJ, Laukes CA, et al.: The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000; 26:25-40
27. Delgado PL, Brannan SK, Mallinckrodt CH, et al.: Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry 2005; 66:686-692
28. Piazza LA, Markowitz JC, Kocsis JH, et al.: Sexual functioning in chronically depressed patients treated with SSRI antidepressants: A pilot study. Am J Psychiatry 1997; 154:1757-1759
29. Gelenberg AJ, McGahuey C, Laukes C, et al.: Mirtazapine substitution in SSRI-induced sexual dysfunction. J Clin Psychiatry 2000; 61:356-360
30. Masand PS, Ashton AK, Gupta S, Frank B: Sustained-release bupropion for selective serotonin reuptake inhibitor-induced sexual dysfunction: A randomized, double-blind, placebo-controlled, parallel-group study. Am J Psychiatry 2001; 158:805-807
31. Saiz-Ruiz J, Montes JM, Ibanez A, et al.: Assessment of sexual functioning in depressed patients treated with mirtazapine: A naturalistic 6-month study. Hum Psychopharmacol 2005; 20:435-440
32. Ashton AK, Mahmood A, Iqbal F: Improvements in SSRI/SNRI-induced sexual dysfunction by switching to escitalopram. J Sex Marital Ther 2005; 31:257-262
33. Taylor MJ, Rudkin L, Hawton K: Strategies for managing antidepressant-induced sexual dysfunction: Systematic review of randomized controlled trials. J Affect Disord 2005; 88:241-254